Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Prevalence of Global Infections and Demand for Novel Therapies
4.2.2 Rise in Research Activities to Develop Novel MRSA Drugs by Key Players and Support by Government Initiatives
4.3 Market Restraints
4.3.1 Lack of Systematic Surveillance for MRSA Infection in Developing Countries
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Lipopeptides
5.1.2 Oxazolidinones
5.1.3 Cephalosporin
5.1.4 Tetracycline
5.1.5 Folate Antagonist
5.1.6 Others
5.2 By Route of administration
5.2.1 Oral Administration
5.2.2 Parenteral
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cumberland Pharmaceuticals Inc
6.1.2 Pfizer Inc
6.1.3 AbbVie Inc.
6.1.4 Melinta Therapeutics Inc
6.1.5 Merck & Co Inc
6.1.6 Theravance Biopharma
6.1.7 Basilea Pharmaceutica
6.1.8 AmpliPhi Biosciences Corporation
6.1.9 Teva Pharmaceutical Industries ltd
6.1.10 Debiopharm International S.A.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS